Krka, d. d. (LJSE:KRKG)

Market Cap	7.54B +18.7%
Revenue (ttm)	2.11B +7.1%
Net Income	417.65M +9.6%
EPS	13.75 +10.6%
Shares Out	30.28M
PE Ratio	18.12
Forward PE	17.27
Dividend	9.10 (3.66%)
Ex-Dividend Date	Jul 21, 2026

Volume	23,601
Open	249.00
Previous Close	249.00
Day's Range	247.50 - 249.00
52-Week Range	191.50 - 270.00
Beta	0.45
Analysts	Buy
Price Target	255.50 (+2.61%)
Earnings Date	Nov 12, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 13,300
• Stock Exchange: Ljubljana Stock Exchange
• Ticker Symbol: KRKG

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Analyst Summary

According to 6 analysts, the average rating for KRKG stock is "Buy." The 12-month stock price target is €255.50, which is an increase of 2.61% from the latest price.

Price Target

€255.50

(2.61% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 4, 2026

Data Sources Report a data error